宝济药业递表港交所 中信证券、海通国际为联席保荐人

Core Viewpoint - Baoji Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities and Haitong International as joint sponsors [1] Company Overview - Baoji Pharmaceutical is a clinical-stage biotechnology company focused on developing recombinant biopharmaceuticals in China using synthetic biology [1] - The company has seven candidate drugs across four therapeutic areas, including three core products: KJ017, KJ103, and SJ02, along with five preclinical assets [1] Intellectual Property - The core products are protected by intellectual property rights globally, with 9 authorized patents and 10 patent applications [1] Product Development - KJ017 is designed for large-volume subcutaneous administration, KJ103 targets autoimmune diseases, and SJ02 is for assisted reproduction [1] - All core products are in late clinical stages or NDA registration stages in China [1] Production and Strategy - The company possesses commercial-scale production capabilities and implements a "two-antibody" strategy, focusing on the development of subcutaneous formulations for antibody drugs and antibiotics [1] - The business model combines in-house research and external collaborations, ensuring cost-effectiveness and standardized production capabilities [1]